25 April 2017 - Clinigen Group's Idis Managed Access division and Onxeo have agreed to launch a Managed Access programme for belinostat (Beleodaq) in Europe. Belinostat is for use in patients with relapsed or refractory peripheral T-cell lymphoma (PTCL).

PTCL is a form of blood cancer comprising of a group of rare and aggressive non-Hodgkin lymphomas (‘NHLs’), a malignant lymphoproliferative disorder. PTCL accounts for approximately 10%-15% of all NHL cases.

Belinostat is a histone deacetylase inhibitor used to treat refractory or relapsed PTCL. The product received accelerated approval by the US FDA in July 2014 due to the unmet medical need in this rare disease. There are no approved treatments for PTCL in Europe.

Read Clinigen press release